TMCI Logo

Treace Medical Concepts, Inc. (TMCI) 

NASDAQ
Market Cap
$485.29M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
43 of 775
Rank in Industry
1 of 99

Largest Insider Buys in Sector

TMCI Stock Price History Chart

TMCI Stock Performance

About Treace Medical Concepts, Inc.

Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, …

Insider Activity of Treace Medical Concepts, Inc.

Over the last 12 months, insiders at Treace Medical Concepts, Inc. have bought $7.31M and sold $0 worth of Treace Medical Concepts, Inc. stock.

On average, over the past 5 years, insiders at Treace Medical Concepts, Inc. have bought $3.11M and sold $106.84M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Treace John T. (Chief Executive Officer) — $3.73M. TREACE JAMES T (director) — $2.07M. BAKEWELL JOHN K (director) — $1.19M.

The last purchase of 50,000 shares for transaction amount of $265,630 was made by Treace John T. (Chief Executive Officer) on 2024‑09‑16.

List of Insider Buy and Sell Transactions, Treace Medical Concepts, Inc.

2024-09-16PurchaseChief Executive Officer
50,000
0.0853%
$5.31$265,630+7.09%
2024-08-15Purchasedirector
84,000
0.1435%
$5.96$501,0350.00%
2024-08-14PurchaseChief Executive Officer
85,000
0.1461%
$6.00$510,3150.00%
2024-06-11PurchaseChief Executive Officer
45,000
0.0729%
$5.88$264,600+1.03%
2024-05-31Purchasedirector
25,000
0.0415%
$6.05$151,328+0.09%
2024-05-29Purchasedirector
25,000
0.0397%
$5.20$130,063+11.17%
2024-05-28Purchasedirector
50,000
0.0809%
$5.07$253,475+16.04%
2024-05-24Purchasedirector
18,000
0.0299%
$5.19$93,501+13.47%
2024-05-22Purchasedirector
12,100
0.0183%
$4.99$60,425+9.29%
2024-05-17PurchaseChief Executive Officer
100,000
0.156%
$5.56$556,170+15.80%
2024-05-14PurchaseChief Executive Officer
150,000
0.2476%
$5.12$767,805+16.50%
2024-05-14Purchasedirector
19,356
0.0323%
$5.17$100,001+16.50%
2024-05-13PurchaseChief Executive Officer
150,000
0.2433%
$4.56$683,490+27.53%
2024-05-13Purchasedirector
145,000
0.2342%
$4.54$657,981+27.53%
2024-05-13Purchasedirector
36,802
0.0573%
$4.38$161,090+27.53%
2024-05-10PurchaseChief Executive Officer
150,000
0.2529%
$4.58$686,880+31.96%
2024-05-10Purchasedirector
83,198
0.1399%
$4.57$379,849+31.96%
2024-05-10Purchasedirector
83,000
0.1384%
$4.53$376,023+31.96%
2024-05-10Purchasedirector
130,000
0.2189%
$4.57$594,620+31.96%
2024-05-10Purchasedirector
25,000
0.0414%
$4.50$112,568+31.96%

Insider Historical Profitability

4.97%
Treace John T.Chief Executive Officer
6523095
10.4709%
$7.791215+15.13%
TREACE JAMES Tdirector
1223441
1.9639%
$7.79632
MOTT RICHARD Wdirector
1072944
1.7223%
$7.79419
BAKEWELL JOHN Kdirector
135048
0.2168%
$7.7910
Jain Deeptidirector
31235
0.0501%
$7.7910

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$56.16M6.944.3M+0.22%+$125,410.50<0.01
BlackRock$48.29M5.973.7M+0.23%+$108,249.75<0.01
Morgan Stanley$42.96M5.313.29M+5.59%+$2.28M<0.01
Armistice Capital Llc$31.32M3.872.4M-15.97%-$5.95M0.1
William Blair Investment Management$30.4M3.762.33M-18.78%-$7.03M0.08
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.